Point-of-Care Diagnostics Kit Market Scope
Point-of-care (PoC) diagnostics kits are medical tests kit that is performed to allow for quick analysis and outcomes. Various portable tools for glucose monitoring, infectious disease, cardio-metabolic, and urinalysis testing, among other things, are used in PoC testing. It aids in the early detection of important illnesses, resulting in a more patient-centered healthcare strategy. This type of medical testing is commonly used to provide diagnostic services to remote places where clinical laboratories are difficult to establish. As a result, vital PoC testing equipment is integrated with medical vehicles such as helicopters, air ambulances, planes, and spaceships.
The Point-of-Care Diagnostics Kit market study is segmented by Type (Glucose Monitoring (Strips, Meters, and Lancets), Cardiometabolic testing, Infectious disease testing, Coagulation testing, Pregnancy and fertility testing (Pregnancy testing, and Fertility testing), Tumor / Cancer marker testing, Urinalysis testing, Cholesterol testing, Hematology testing, Drugs-of-abuse testing, Fecal occult testing and Others), by Application (Cardiometabolic testing, Infectious disease testing, Nephrology testing, Drug-of-Abuse (DoA) testing, Blood glucose testing, Pregnancy testing, Cancer biomarker testing and Other) and major geographies with country level break-up.
Some of the companies' favored market-exploration techniques include mergers and acquisitions, expansions, investments, new service launches, and collaborations. The company is giving its fair share of the company's expansion. The market for point-of-care diagnostics is moderately competitive, with several prominent competitors. Few big firms currently dominate the market in terms of market share. Other businesses are projected to enter the market as disease frequency rises and the number of the elderly population grows. Abbott, Siemens AG, Becton, Dickinson and Company, and F. Hoffmann-La Roche Ltd are among the market's key players.
Abbott Laboratories (United States), Siemens Healthineers AG (Germany), Quidel Corporation (United States), F. Hoffman-La Roche Ltd. (Switzerland), Danaher Corporation (United States), Becton (United States), Dickinson and Company (United States), Chembio Diagnostics (United States), EKF Diagnostics (United Kingdom) and Trinity Biotech plc (Ireland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Nova Biomedical (United States), PTS Diagnostics (United States), Sekisui Diagnostics (United States) and Thermo Fisher Scientific (United States).
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
Segmentation Overview
AMA Research has segmented the market of Global Point-of-Care Diagnostics Kit market by Type, Application and Region.
On the basis of geography, the market of Point-of-Care Diagnostics Kit has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In Jan 2022, Roche launched their Cobas Pulse System in countries that accept the CE Mark. Roche Diagnostics has released the latest generation of integrated point-of-care solutions for professional blood glucose management. and In Oct 2021, Thermo Fisher Scientific has acquired FDA Emergency Use Authorization (EUA) to execute COVID-19 tests with the Spectrum Solutions SpectrumDNA SDNA-1000 collection equipment, a high-throughput, automated COVID-19 testing system on the Amplitude Solution.
Market Trend
- Blood Glucose Testing Has A High Demand in the Market
- Increasing Research Activities for the Development of Innovative Imaging
Market Drivers
- The Increasing Disease Prevalence among the Developing Country
- The Rise in Geriatric Population Base Globally
- An Increasing Number of Pathology Labs and Services with Modern Diagnostic Techniques Are Being Established
Opportunities
- Increasing Technological Advancement in a Developing Country
- Increasing Investment in R&D Departments
Restraints
- The Limited Availability of Medical and Lab Testing Facilities
- High Cost of Product Development
Challenges
- Strict Government Regulation
Key Target Audience
Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Investors